Impact of breast cancer therapy on vaginal health and sexuality

The microbiome study presented by Dr Nynke Willers from University Hospitals Leuven investigates the impact of breast cancer therapy on the vaginal microbiome and its associated sexual implications. Premenopausal breast cancer patients, willing to participate, undergo three gynaecological examinations wherein the vaginal microbiome is analyzed. Simultaneously, participants complete surveys addressing sexual health. The study aims to find meaningful correlations between these parameters.

While local estrogen application remains a safe option, certain patients decline this form of treatment. By directing attention to the vaginal microbiome during the menopausal transition in breast cancer therapy, alternatives for addressing vaginal discomfort are sought.

It is the first prospective study of the sexual implications of breast cancer treatment. Furthermore, it represents the first longitudinal examination of the vaginal microbiome across distinct stages of breast cancer treatment.

Reference:

Willers N, Impact of iatrogenic menopause on vaginal health and sexuality. SABCS 2023, #PO4-20-06